Back to search results

Pencil Beam Scanning for Renal Tumors in Children and Young Adults

This study is looking at a special type of radiation called proton beam radiation using pencil beam scanning for patients with kidney tumors, specifically Wilms tumor or clear cell sarcoma. This treatment aims to deliver radiation more precisely to the tumor area. The main goal is to see if this treatment causes fewer side effects, especially stomach and gut problems, within 90 days after starting radiation. It also aims to see if it can shorten the total time you need radiation therapy and deliver lower doses to healthy organs. This study is for patients aged 0 to 30 years who need radiation for their kidney tumor. The current status of the study is unclear, and it plans to enroll 28 patients.

Study design
This is a pilot study, meaning it's an early look at this treatment. It plans to enroll 28 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will assess side effects for 90 days after the start of proton therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03810651

Pencil Beam Scanning in Patients With Renal Tumors

Recruiting
EARLY_PHASE1Ages 0–30InterventionalTreatment
Children's Hospital of Philadelphia
~28 participants
Updated 2026-04-15 on ClinicalTrials.gov
What's tested:Proton beam radiation using pencil beam scanning

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of any non-hematologic toxicity that occurs within 90 days following the start of proton therapy assessed with with NCI Common toxicity criteria (CTC Version 4.0) grades].
Measured over 90 days

Conditions

Renal Tumor
Wilms Tumor

Explore related trials

Clear Cell Sarcoma of the KidneyWilms Tumor

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Christine Hill-Kayser, MD · PRINCIPAL_INVESTIGATOR · Children's Hospital of Philadelphia

Who to contact

Christine Hill-Kayser, MD
[email protected]
215-590-2810
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Less than 30 years of age
Diagnosis
The patient is a candidate for external beam radiotherapy based on standard of care for treatment of Wilms tumor or CCSK

Exclusion

Prior radiotherapy to the region of the study cancer
Chemotherapy administered for diagnosis of Wilms tumor or CCSK
Pregnant or breastfeeding

What this trial measures

  • Occurrence of any non-hematologic toxicity that occurs within 90 days following the start of proton therapy assessed with with NCI Common toxicity criteria (CTC Version 4.0) grades].90 days

    Acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors. Acute toxicity is defined as any non-hematologic toxicity that occurs within 90 days following the start of proton therapy. NCI Common toxicity criteria (CTC Version 4.0) grades will be employed. Individual category content listings are available to investigators at http://ctep.cancer.gov, with attention to the following System Organ Classes and CTCAE Adverse Events: General Disorders and Administration Site Conditions, Hepatobiliary Disorders, Blood and Lymphatic System Disorders, Gastrointestinal Disorders, Renal and Urinary Disorders, Injury, poisoning, or procedural complications, Metabolism and nutrition disorders, and Benign, Malignant, and Unspecified Neoplasms.